Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

• Status: Completed
• Trial end date: 2017-05-24

Summary

Primary Objective:

To evaluate the safety and potential efficacy of eculizumab to prevent AMR in sensitized recipients of deceased donor kidney transplants.

• Phase: Phase 2

Details

• Lead Sponsor: Alexion Pharmaceuticals
• Treatments: Eculizumab